Human CD30 Ligand/TNFSF8 APC-conjugated Antibody Summary
Gln63-Asp234
Accession # P32971
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CD30 Ligand/TNFSF8 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA and 200 ng/mL Calcium Ionomycin overnight were stained with Mouse Anti-Human CD3e PE-conjugated Monoclonal Antibody (Catalog # FAB100P) and either (A) Mouse Anti-Human CD30 Ligand/TNFSF8 APC-conjugated Monoclonal Antibody (Catalog # FAB1028A) or (B) Mouse IgG2BAllophycocyanin Isotype Control (Catalog # IC0041A). View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: CD30 Ligand/TNFSF8
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a costimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. Human and mouse CD30 ligand cDNAs share 70% sequence homology.
- Brunangelo, F. et al. (1995) Blood 85:1.
- Gruss, H.-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
- Chiarle, R. et al. (1999) J. Immunol. 163:194.
Product Datasheets
Citation for Human CD30 Ligand/TNFSF8 APC-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors
Authors: AA Hombach, G Rappl, H Abken
Mol. Ther., 2019-06-19;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD30 Ligand/TNFSF8 APC-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD30 Ligand/TNFSF8 APC-conjugated Antibody and earn rewards!
Have you used Human CD30 Ligand/TNFSF8 APC-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
